CTLA4 and melanoma: Combination of pharmacological inhibition and anti-CTLA-4 antibody led to rejection of established tumors and resistance to secondary challenge in mice after inoculation with melanoma cells, which was mainly achieved through restored CD8+ and CD4+ T cells activity.